Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 4/20 | 0.50 |
| ▸ | SLC18A3 | Q16572 | 3/20 | 0.50 |
| ▸ | MAOB | P27338 | 3/20 | 0.50 |
| ▸ | MAOA | P21397 | 1/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | FPR1 | P21462 | 2/20 | 0.45 |
| ▸ | FPR2 | P25090 | 2/20 | 0.45 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.45 |
| ▸ | HTR1B | P28222 | 1/20 | 0.45 |
| ▸ | HTR2A | P28223 | 1/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL407883 | 1.00 | KDM1A (0.50) | KDM1ASLC18A3MAOBMAOASIGMAR1 | |
| SCHEMBL8870050 | 1.00 | KDM1A (0.50) | KDM1ASLC18A3MAOBMAOASIGMAR1 | |
| SCHEMBL8471748 | 1.00 | KDM1A (0.50) | KDM1ASLC18A3MAOBMAOASIGMAR1 | |
| SCHEMBL11565322 | 1.00 | KDM1A (0.50) | KDM1ASLC18A3MAOBMAOASIGMAR1 | |
| SCHEMBL11565325 | 1.00 | KDM1A (0.50) | KDM1ASLC18A3MAOBMAOASIGMAR1 | |
| Hydrochloric Acid SCHEMBL11555721 | 0.98 | SLC18A3 (0.49) | KDM1ASLC18A3MAOBMAOASIGMAR1 | |
| Hydrochloric Acid SCHEMBL11555730 | 0.98 | SLC18A3 (0.49) | KDM1ASLC18A3MAOBMAOASIGMAR1 | |
| Hydrochloric Acid SCHEMBL442396 | 0.98 | SLC18A3 (0.49) | KDM1ASLC18A3MAOBMAOASIGMAR1 | |
| Bicarbonate SCHEMBL7443967 | 0.95 | MAPT (0.49) | KDM1ASLC18A3MAOBMAOASIGMAR1 | |
| SCHEMBL5923778 | 0.85 | SLC18A3 (0.54) | KDM1ASLC18A3MAOBMAOASIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0630887-B1 | 4-(aryl-substituted)-piperidines as neurokinin receptor antagonists | ZENECA LTD (GB) | 1999-07-28 | — | — | EP | claimed |
| US-5654299-A | TREATING RESPIRATORY SYSTEM DISORDER (I.E. ASTHMA) WITH NEUROKININ 2 RECEPTOR ANTAGONIST | ZENECA LIMITED (GB) | 1997-08-05 | — | — | US | claimed |
| US-20080312271-A1 | AZABENZIMIDAZOLYL COMPOUNDS | PFIZER INC. | 2008-12-18 | — | — | US | disclosed |
| US-20080280933-A1 | BENZIMIDAZOLYL COMPOUNDS | EFREMOV IVAN | 2008-11-13 | — | — | US | disclosed |
| US-5654299-A | TREATING RESPIRATORY SYSTEM DISORDER (I.E. ASTHMA) WITH NEUROKININ 2 RECEPTOR ANTAGONIST | ZENECA LIMITED (GB) | 1997-08-05 | — | — | US | disclosed |
| US-4132710-A | DIURETICS, ANOREXICS, ANTIDEPRESSANTS, ANTICONVULSANTS, & ANTIHYPERTENSIVE AGENTS | AYERST, MCKENNA AND HARRISON, LTD. (CA) | 1979-01-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280933-A1 | BENZIMIDAZOLYL COMPOUNDS | PAICS, TMBIM6, ABCG2 | KDM1A 3628/4885SLC18A3 1341/4885MAOB 289/4885 |
| US-20080312271-A1 | AZABENZIMIDAZOLYL COMPOUNDS | AZI2, PAICS, UGT2B7 | KDM1A 2147/4885SLC18A3 1289/4885MAOB 79/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.